Stock Traders Purchase Large Volume of Microbot Medical Call Options (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT) was the target of some unusual options trading activity on Thursday. Stock traders acquired 9,085 call options on the stock. Thisrepresentsanincreaseofapproximately206% compared to the average volume of 2,967 call options.

Analyst Ratings Changes

Separately, Wall Street Zen raised Microbot Medical from a “sell” rating to a “hold” rating in a research note on Saturday, June 14th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $9.00.

Microbot Medical Trading Up 8.1%

NASDAQ:MBOT opened at $3.85 on Friday. Microbot Medical has a 12-month low of $0.82 and a 12-month high of $3.94. The stock has a 50-day moving average price of $2.72 and a 200 day moving average price of $2.30. The stock has a market capitalization of $175.37 million, a P/E ratio of -6.64 and a beta of 1.15.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). On average, research analysts predict that Microbot Medical will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Microbot Medical

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in shares of Microbot Medical in the fourth quarter worth about $118,000. Geode Capital Management LLC lifted its holdings in shares of Microbot Medical by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 10,442 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Microbot Medical during the first quarter valued at $42,000. Goldman Sachs Group Inc. purchased a new stake in shares of Microbot Medical during the first quarter valued at $57,000. Finally, XTX Topco Ltd purchased a new stake in shares of Microbot Medical during the second quarter valued at $43,000. 16.30% of the stock is owned by institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.